Abstract
Probenecid (PROB) has been widely used for long time for different clinical purposes, from gout treatment to designs as a coadjutant for antibiotic agents. Among its many properties, the ability of PROB to preserve high concentrations of several metabolites and other agents in the CNS, together with its relative lack of side-effects, have made this drug a valuable pharmacological tool for clinical and basic research. Nowadays, biomedical research offers evidence about new targets for PROB that may help to explain its many beneficial actions. In this regard, despite most of its protective actions in the brain have been largely related to its capacity to accumulate the inhibitory metabolite kynurenic acid to further inhibit the glutamate-related excitotoxicity in different animal models of neurological disorders, in this review we describe the basic aspects of PROB’s pharmacokinetics and mechanisms of action and discuss other alternative targets recently described for this drug that may complement its pattern of activity in the CNS, including its role as anti-inflammatory and anti-nociceptive agent when targeting different key proteins.
Keywords: Probenecid, clinical perspectives, pharmacokinetics, neuroprotective mechanisms, neurotransmitter modulation, neurological disorders.
CNS & Neurological Disorders - Drug Targets
Title:Probenecid: An Emerging Tool for Neuroprotection
Volume: 12 Issue: 7
Author(s): Ana Laura Colín-González and Abel Santamaría
Affiliation:
Keywords: Probenecid, clinical perspectives, pharmacokinetics, neuroprotective mechanisms, neurotransmitter modulation, neurological disorders.
Abstract: Probenecid (PROB) has been widely used for long time for different clinical purposes, from gout treatment to designs as a coadjutant for antibiotic agents. Among its many properties, the ability of PROB to preserve high concentrations of several metabolites and other agents in the CNS, together with its relative lack of side-effects, have made this drug a valuable pharmacological tool for clinical and basic research. Nowadays, biomedical research offers evidence about new targets for PROB that may help to explain its many beneficial actions. In this regard, despite most of its protective actions in the brain have been largely related to its capacity to accumulate the inhibitory metabolite kynurenic acid to further inhibit the glutamate-related excitotoxicity in different animal models of neurological disorders, in this review we describe the basic aspects of PROB’s pharmacokinetics and mechanisms of action and discuss other alternative targets recently described for this drug that may complement its pattern of activity in the CNS, including its role as anti-inflammatory and anti-nociceptive agent when targeting different key proteins.
Export Options
About this article
Cite this article as:
Colín-González Laura Ana and Santamaría Abel, Probenecid: An Emerging Tool for Neuroprotection, CNS & Neurological Disorders - Drug Targets 2013; 12 (7) . https://dx.doi.org/10.2174/18715273113129990090
DOI https://dx.doi.org/10.2174/18715273113129990090 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
3D-QSAR Assisted Design of Novel 7-Deazapurine Derivatives as TNNI3K Kinase Inhibitors Using Molecular Docking and Molecular Dynamics Simulation
Letters in Drug Design & Discovery Effect of Cardiovascular Injury on Catabolism of Adenosine and Adenosine 5-‘Triphosphate in Systemic Blood in a Freely Moving Rat Model In Vivo
Drug Metabolism Letters Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Single Nucleotide Polymorphisms in Neonatal Necrotizing Enterocolitis
Current Pediatric Reviews Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry Editorial [Hot topic: Crucial Role of Redox Signaling in the Regulation of Heart Health (Guest Editor: Dipak K. Das)]
Current Cardiology Reviews Pharmacological Activity of Cardiovascular Agents from Herbal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Pharmacology of the Glycine Receptor Chloride Channel
Current Pharmaceutical Design MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Current Drug Targets Resveratrol Protects Endothelial Cells from Rapid Stretch Injury and Hypoxia In Vitro
Current Drug Therapy Endotoxin, TLR4 Signaling and Vascular Inflammation: Potential Therapeutic Targets in Cardiovascular Disease
Current Pharmaceutical Design Ryanodine Receptor Patents
Recent Patents on Biotechnology Sulforaphane Treatment of Young Men with Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Biomarkers of Subclinical Atherosclerosis and Natural Products as Complementary Alternative Medicine
Current Pharmaceutical Design Death Receptor Activation-Induced Hepatocyte Apoptosis and Liver Injury
Current Molecular Medicine Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer’s Disease
Current Drug Targets Carbon Nanotube: A Versatile Carrier for Various Biomedical Applications
Drug Delivery Letters Processed Foods, Dysbiosis, Systemic Inflammation, and Poor Health
Current Nutrition & Food Science Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface
Recent Patents on CNS Drug Discovery (Discontinued) Stem Cell Therapy for the Treatment of Myocardial Infarction
Current Pharmaceutical Design